You are seeing these quotes based on previous browsing related to sectors such as
Latest | Forecast | |
---|---|---|
Div Yield | 0.0% | n/a |
Div Cover | n/a | n/a |
Op Mrgn | 2.2% | n/a |
ROCE | 2.8% |
Latest | Forecast | |
---|---|---|
P/E | 28.1 | n/a |
PEG | 0.0 | n/a |
Price / Revenue | 3.5 | n/a |
Price / Book value | 4.0 |
Latest | Forecast | |
---|---|---|
Revenue | 96.5% | 11.5% |
PBT | 0.0% | n/a |
EPS | 0.0% | 44.1% |
DPS | n/a | 0.0% |
Year Ending | Revenue ($m) |
Pre-tax ($m) |
EPS | P/E | PEG | EPS Growth | Div | Yield |
---|---|---|---|---|---|---|---|---|
2019-12-31 | 204.89 | -141.10 | $-0.16 | -31.5 | 0.0 | n/a | n/a | 0.0% |
2020-12-31 | 227.98 | -189.73 | $-0.18 | -34.9 | 0.0 | n/a | n/a | 0.0% |
2021-12-31 | 356.13 | -215.74 | $0.00 | -2,840.3 | 0.0 | n/a | n/a | 0.0% |
2022-12-31 | 426.41 | -410.42 | $-0.43 | -7.4 | 0.0 | n/a | n/a | 0.0% |
2023-12-31 | 838.00 | 58.31 | $0.12 | 30.0 | 0.0 | n/a | n/a | 0.0% |
Hutchmed cancer treatment indication accepted for review in China Sharecast News | 28 Mar |
---|---|
Hutchmed partner Inmagene exercises options over two drug candidates Sharecast News | 02 Feb |
Hutchmed's 'Elunate' approved under new Hong Kong rules Sharecast News | 30 Jan |
LTIP and Share Option Scheme | 14-Mar-24 10:16 |
---|---|
Vesting of awards under the LTIP | 05-Mar-24 08:30 |
2023 Full Year Results and Business Updates | 28-Feb-24 11:30 |
HUTCHMED to Announce 2023 Final Results | 01-Feb-24 08:31 |
Total Voting Rights | 29-Dec-23 08:32 |